# Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza

> **NCT06817096** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Azidus Brasil** · enrollment: 340 (estimated)

## Conditions studied

- Covid 19
- Influenza

## Interventions

- **DRUG:** Nitazoxanide 600Mg Oral Tablet / placebo oral tablet

## Key facts

- **NCT ID:** NCT06817096
- **Lead sponsor:** Azidus Brasil
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02
- **Primary completion:** 2026-12
- **Final completion:** 2027-06
- **Target enrollment:** 340 (ESTIMATED)
- **Last updated:** 2025-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06817096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06817096, "Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06817096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*